ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1458

Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity

Kittikorn Wangriatisak1, Francesca Faustini2, Charlotte de Vries3, Ravi Kumar Sharma4, Caroline Grönwall5, Prapaporn Pisitkun6, Patchanee Chootong7, Vivianne Malmström5 and Iva Gunnarsson8, 1Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Thailand ; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 2Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5Karolinska Institutet, Stockholm, Sweden, 6Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bankok, Thailand, 7Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, 8Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Sweden, Stockholm, Sweden

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), B-Lymphocyte, immunology, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is characterized by abnormal B-cell activation and their subsequent differentiation into autoreactive plasma blasts/cells. The heterogeneity of autoreactive B cell subsets and their contribution to the pathogenesis of LN are not well elucidated.

Methods: Thirty-five SLE patients, including twenty-eight with positive anti-dsDNA antibodies (80%), and fifteen healthy controls were recruited in this study. Data are represented as median and interquartile range (IQR). To identify DNA-reactive B cells, a surrogate peptide (DWEYSVWLSN) that serves as dsDNA mimotope was used, as previously shown (Jacobi, Annett M et al. 2009 and Wangriatisak, Kittikorn et al. 2021). The phenotype of peripheral B cell subsets (SLE, n = 37 from 35 patients and HCs, n = 15) and DNA-reactive B cells (SLE, n = 10 and HCs, n = 6) was analyzed by spectral flow cytometry. Correlations between different B-cell subsets and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, clinical manifestations, and laboratory parameters were assessed.

Results: In SLE patients, the median SLEDAI-2K score was 9 (4-17), median age and disease duration were 34 (28-46) and 9 (1.5-13.0), respectively. Twenty-one patients presented with lupus nephritis (LN), with proliferative (class III, n = 3 and class IV, n = 4), membranous (class V, n = 7) and mixed histological patterns (class III & V, n = 5 and class IV & V, n = 2). Phenotypic analyses showed an expansion of circulating activated naïve (aNAV: CD11c+CD21–CD27–IgD+, p < 0.01), double negative 2 B cells (DN2: CD11c+CD21–CD27–IgD–, p < 0.05) and plasmablasts (PB: CD27hiCD38hi, p < 0.05) in LN patients, especially in class V, compared to non-LN and age-matched HCs. Intriguingly, an upregulation of CD71, as well as a downregulation of CD95, was observed on both DN2 and PB from patients with LN. Further analysis showed that expansion of DNA-reactive B cells was observed in LN patients (median (IQR): 0.13% (0.095-0.160)) compared with non-LN patients (median (IQR): 0.056% (0.042-0.070), p < 0.05). Surprisingly, the majority of these autoreactive cells were mostly represented by an activated naïve phenotype (CD11c+CXCD5–CD21–), which was more frequent in patients with LN. The percentage of aNAV B cells were positively associated with DN2 (r = 0.567, p = 0.0003) and PB (r = 0.498, p = 0.002), especially in patients with LN. These expanded aNAV, DN2 and PB showed a significant positive correlation with the SLEDAI-2K index, and were inversely correlated with C3 and C4 levels in LN patients. Furthermore, DN2 and aNAV B cells were expanded in anti-dsDNA positive patients, while a lower frequency of such cells was found in anti-Smith positive patients.

Conclusion: Our data show that aNAV B cells display autoreactivity to dsDNA. The cooperation between these cells and DN2 and PB might be involved in the generation of anti-dsDNA antibody in LN which proceed of these B cell responses might via the extrafollicular pathway.


Disclosures: K. Wangriatisak: None; F. Faustini: None; C. de Vries: None; R. Kumar Sharma: None; C. Grönwall: None; P. Pisitkun: None; P. Chootong: None; V. Malmström: Eli Lilly, 1, Janssen, 5, ONO, 1, Pfizer, 5; I. Gunnarsson: None.

To cite this abstract in AMA style:

Wangriatisak K, Faustini F, de Vries C, Kumar Sharma R, Grönwall C, Pisitkun P, Chootong P, Malmström V, Gunnarsson I. Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/activated-naive-dna-reactive-b-cells-in-lupus-nephritis-patients-are-increased-and-associated-with-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activated-naive-dna-reactive-b-cells-in-lupus-nephritis-patients-are-increased-and-associated-with-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology